About AIxMed
AIxMed is a healthcare AI company dedicated to transforming cancer diagnosis and monitoring through its computational cytology platform. The company’s core mission is to digitize 3D cytology samples rapidly and extract clinical insights to improve patient care. Their flagship application, AIxURO™, is designed to assist in bladder cancer diagnosis using The Paris System for Reporting Urinary Cytology (TPS).
For physicians, AIxMed’s technology offers an AI-powered platform that aims to enhance cytology insights, improve workflows, and elevate the quality of patient care in the fight against cancer. AIxURO™ specifically supports the analysis of non-invasive urine cytology specimens, with the goal of improving diagnostic accuracy and workflow efficiency in bladder cancer assessment. It identifies suspicious and atypical cells from urine samples, providing quantitative and qualitative data based on The Paris System (TPS). This can potentially reduce the need for invasive procedures like cystoscopies, improve patient compliance, and contribute to more cost-effective healthcare. AIxMed emphasizes that AI in medicine is an assistant, not a replacement, and clinical judgment remains in human hands. The platform also aims to bring consistency, structure, and efficiency to cytology review workflows.
Focus Areas
Business Intelligence
| Technology | AI-powered computational cytology platform, cloud-native, AI-driven digital pathology ecosystem, Z-plane scanning technology |
What Physicians Need to Know
For physicians, AIxMed's solutions, particularly AIxUROu2122, offer automated prioritization, standardized data, and structured assisted workflows for cytology review, which can significantly reduce the time needed for diagnosis and enhance accuracy and speed in detecting cancerous cells. This AI-assisted approach can help triage cases, improve quality control, and make work more efficient. The technology is designed to support clinical decision-making, potentially reducing the frequency of invasive procedures like cystoscopies, enhancing patient compliance, and contributing to more cost-effective healthcare. AIxMed emphasizes that AI in medicine is an assistant, not a replacement, ensuring clinical judgment remains in human hands while boosting accuracy.
AIxMed's AIxUROu2122 is designed for seamless integration into existing laboratory environments and digital pathology infrastructures. They have established partnerships with leading digital pathology providers like Lumea, integrating AIxUROu2122 into Lumea's FDA-cleared digital pathology platform, which is utilized by a significant portion of the U.S. urology market. AIxMed also collaborates with diagnostic laboratories such as PathNet and Biopticka Laboratou0159 to integrate their technology into their workflows and Laboratory Information Systems (LIS). The platform is built for compatibility across various digital pathology environments.
Videos
News, demos, and interviews about AIxMed.
Videos load interactively. If none appear, search YouTube for AIxMed →
Frequently Asked Questions
Related Companies
LabSense AI (labsense.ai) is an AI-powered medical lab result interpreter designed to democratize medical literacy globally. The platform aims to help patients understand their lab results in plain language, regardless of their education level or location. It processes lab reports (PDF or photo uploads) and provides explanations for over 86 lab tests, including blood count, […]
OptraSCAN is a California-based digital pathology company that provides high-throughput scanners, AI-powered diagnostics, and enterprise image management solutions for modern pathology labs. OptraSCAN’s AI solutions are purpose-built for various pathology challenges, including HistoSiA™ for histology (e.g., breast cancer IHC biomarker analysis), CytoSiA™ for cytology (e.g., cervical cancer screening), and BactoSiA™ for bacteriology (e.g., TB detection […]
NeuraMetrix is a Software as a Medical Device (SaMD) company that has developed a novel digital biomarker for the detection and monitoring of neurological diseases and psychiatric disorders. The company’s core technology, NeuraMetrix Typing Cadence (TC), passively measures typing inconsistency during normal computer use. This inconsistency serves as a highly accurate indicator of cognitive and […]
Indica Labs is a global leader in AI-powered digital pathology software and services, providing comprehensive solutions for quantitative evaluation and management of whole slide images. Their flagship platforms, HALO® and HALO AI, leverage artificial intelligence and computer vision algorithms to enable fast and precise analysis of tissue samples, which is critical for advancing research and […]
Triomics is an oncology AI company dedicated to transforming how cancer centers manage complex clinical information. The company’s platform utilizes AI agents to meticulously read and interpret comprehensive longitudinal patient records, converting unstructured clinical data—such as notes, pathology reports, imaging results, and genomic panels—into structured, verifiable outputs. This process significantly reduces the manual burden on […]
Cercare Medical is an AI-powered healthcare company specializing in advanced perfusion imaging solutions for neurological diseases. Their software, the Cercare Medical Neurosuite, processes CT, CBCT, and MRI data to provide detailed insights into brain health. This technology goes beyond traditional perfusion imaging by integrating proprietary biomarkers that measure not only blood flow but also oxygenation, […]
